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Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune dis-
ease characterized by formation of autoantibodies against nuclear 
antigens, including nucleic acids. Antiviral type I IFNs induced by 
innate immune recognition of nucleic acids play a central role in 
the initiation and perpetuation of SLE (1–3). Type I IFNs have pro-
nounced immunostimulatory effects that promote loss of B cell self-
tolerance and autoantibody production. Antinuclear antibodies 
(ANAs) form complexes with nuclear antigens released from dying 
cells (4, 5), and deposition of such immune complexes in the cap-
illary bed followed by local complement and leukocyte activation 
results in destructive tissue inflammation. SLE flares are commonly 
triggered by viral infection or UV irradiation (6, 7). The latter can 
provoke not only cutaneous symptoms, but also systemic disease.
Genome integrity is continuously challenged by the DNA damage that arises during normal cell metabolism. Biallelic 
mutations in the genes encoding the genome surveillance enzyme ribonuclease H2 (RNase H2) cause Aicardi-Goutières 
syndrome (AGS), a pediatric disorder that shares features with the autoimmune disease systemic lupus erythematosus 
(SLE). Here we determined that heterozygous parents of AGS patients exhibit an intermediate autoimmune phenotype and 
demonstrated a genetic association between rare RNASEH2 sequence variants and SLE. Evaluation of patient cells revealed 
that SLE- and AGS-associated mutations impair RNase H2 function and result in accumulation of ribonucleotides in genomic 
DNA. The ensuing chronic low level of DNA damage triggered a DNA damage response characterized by constitutive p53 
phosphorylation and senescence. Patient fibroblasts exhibited constitutive upregulation of IFN-stimulated genes and an 
enhanced type I IFN response to the immunostimulatory nucleic acid polyinosinic:polycytidylic acid and UV light irradiation, 
linking RNase H2 deficiency to potentiation of innate immune signaling. Moreover, UV-induced cyclobutane pyrimidine 
dimer formation was markedly enhanced in ribonucleotide-containing DNA, providing a mechanism for photosensitivity in 
RNase H2–associated SLE. Collectively, our findings implicate RNase H2 in the pathogenesis of SLE and suggest a role of DNA 
damage–associated pathways in the initiation of autoimmunity.
Defective removal of ribonucleotides from DNA 
promotes systemic autoimmunity
Claudia Günther,1 Barbara Kind,2 Martin A.M. Reijns,3 Nicole Berndt,1 Manuel Martinez-Bueno,4 Christine Wolf,2 Victoria Tüngler,2 
Osvaldo Chara,5,6 Young Ae Lee,7 Norbert Hübner,7 Louise Bicknell,3 Sophia Blum,2 Claudia Krug,2 Franziska Schmidt,2  
Stefanie Kretschmer,2 Sarah Koss,2 Katy R. Astell,3 Georgia Ramantani,8 Anja Bauerfeind,7 David L. Morris,9  
Deborah S. Cunninghame Graham,9 Doryen Bubeck,10 Andrea Leitch,3 Stuart H. Ralston,11 Elizabeth A. Blackburn,12  
Manfred Gahr,2 Torsten Witte,13 Timothy J. Vyse,9 Inga Melchers,14 Elisabeth Mangold,15,16 Markus M. Nöthen,15,16,17  
Martin Aringer,18 Annegret Kuhn,19 Kirsten Lüthke,20 Leonore Unger,21 Annette Bley,22 Alice Lorenzi,23 John D. Isaacs,23  
Dimitra Alexopoulou,24 Karsten Conrad,25 Andreas Dahl,24 Axel Roers,25 Marta E. Alarcon-Riquelme,4,26  
Andrew P. Jackson,3 and Min Ae Lee-Kirsch2
1Department of Dermatology and 2Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 3Medical Research Council Human Genetics Unit, MRC 
Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom. 4Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), 
Granada, Spain. 5Center for Information Services and High Performance Computing, Technische Universität Dresden, Dresden, Germany. 6Institute of Physics of Liquids and Biological Systems, National 
University of La Plata, La Plata, Argentina. 7Max Delbrück Centre for Molecular Medicine, Berlin-Buch, Germany. 8Epilepsy Center, University of Freiburg, Freiburg, Germany. 9Genetics and Molecular Medicine, 
King’s College London, London, United Kingdom. 10Department of Life Sciences, Imperial College London, London, United Kingdom. 11Rheumatic Diseases Unit, Centre for Genomic and Experimental Medicine, 
MRC Institute of Genetics and Molecular Medicine, and 12Centre for Translational and Chemical Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom. 13Clinical Immunology, 
Hannover Medical School, Hannover, Germany. 14Clinical Research Unit for Rheumatology, University Medical Center, Freiburg, Germany. 15Institute of Human Genetics, 16German Center for Neurodegenerative 
Diseases (DZNE), and 17Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany. 18Rheumatology, Department of Internal Medicine III, Medizinische Fakultät Carl Gustav Carus, 
Technische Universität Dresden, Dresden, Germany. 19Department of Dermatology, University Hospital, University of Münster, Münster, Germany. 20Schwerpunktpraxis Rheumatologie, Dresden, Germany. 
21Städtisches Klinikum Dresden-Friedrichstadt, Dresden, Germany. 22Department of Pediatrics, University of Hamburg, Hamburg, Germany. 23Institute of Cellular Medicine, Newcastle University, Newcastle upon 
Tyne, United Kingdom. 24Center for Regenerative Therapies Dresden, DFG Cluster of Excellence, and 25Institute for Immunology, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, 
Germany. 26Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
     Related Commentary: p. 102
Authorship note: Claudia Günther, Barbara Kind, and Martin A.M. Reijns contributed 
equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: July 18, 2014; Accepted: October 9, 2014.
Reference information: J Clin Invest. 2015;125(1):413–424. doi:10.1172/JCI78001.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
4 1 4 jci.org   Volume 125   Number 1   January 2015
of ribonucleotides misincorporated in the genome during DNA 
replication (22–25). Ribonucleotides represent the most common 
endogenous base lesion in replicating cells, with more than 1 mil-
lion present in the genome of RNase H2–null mouse cells (23). 
These are normally removed efficiently in a process termed ribo-
nucleotide excision repair (26), whereas absence of cellular RNase 
H2 activity causes large-scale genome instability, p53 pathway 
activation, and early embryonic lethality (23, 24). RNase H2 is 
therefore a key genome surveillance enzyme required for genome 
integrity, raising the question as to how DNA repair may be linked 
to autoimmunity in AGS and SLE.
In the present study, we found that rare variants in RNASEH2 
genes were associated with systemic autoimmunity and estab-
lished that these resulted in impaired ribonucleotide removal. Fur-
thermore, we provided evidence that such embedded ribonucleo-
tides caused increased UV-induced cyclobutane pyrimidine dimer 
(CPD) formation and enhanced type I IFN signaling, thus linking 
mutations in a DNA repair enzyme with systemic autoimmunity.
Results
Carriers of AGS mutations frequently develop SLE-associated auto-
antibodies. Given the phenotypic overlap of AGS with SLE and the 
genetic association of TREX1 with both monogenic chilblain lupus 
Clinical features of SLE alongside type I IFN activation are 
also observed in the rare inflammatory disorder Aicardi-Gout-
ières syndrome (AGS), an early-onset encephalopathy resembling 
congenital viral infection (8–11). AGS is caused by biallelic muta-
tions in each of the 3 subunits of ribonuclease H2 (RNase H2): 
RNASEH2A, RNASEH2B, and RNASEH2C (also known as AGS4, 
AGS2, and AGS3, respectively) (12). Mutations in other enzymes 
involved in the intracellular nucleic acid metabolism — the DNA 
exonuclease 3′ repair exonuclease 1 (TREX1), the triphospho-
hydrolase SAM domain and HD domain-containing protein 1 
(SAMHD1), and the RNA-editing enzyme adenosine deaminase 1 
acting on RNA (ADAR) — have also been implicated in a spectrum 
of autoimmune phenotypes including AGS, familial chilblain 
lupus, and SLE (13–19). In addition, gain-of-function mutations 
in the RNA sensor IFN-induced with helicase C domain 1 (IFIH1) 
can also cause AGS (20). These findings illustrate the importance 
of coordinated pathways that regulate both degradation and sens-
ing of intracellular nucleic acids in order to prevent an inappropri-
ate innate immune response to self-DNA and -RNA (21).
RNase H2 is a heterotrimeric enzyme that can cleave the 
RNA strand of RNA/DNA heteroduplexes, such as those found 
in R-loops, and the 5′ phosphodiester bond of ribonucleotides 
embedded in a DNA duplex, an activity essential for the removal 
Figure 1. Heterozygosity for RNASEH2 mutations promotes systemic autoimmunity. (A) Prevalence of ANAs in heterozygous parents of AGS patients. 
Shown is the percentage of ANA-positive parents of AGS patients (with mutations in TREX1, RNASEH2A–RNASEH2C, or SAMHD1; n = 28; P < 0.001) and in 
parents carrying RNASEH2 mutations (n = 16; P < 0.01, Fisher’s exact test) compared with data from a control population (n = 1,000) measured in the same 
laboratory. (B) RNASEH2B, RNASEH2C, and RNASEH2A gene structures. Variants identified in individuals with SLE (n = 600) are shown in bold above; 
variants in controls (n = 1,056) are shown below (boxes indicate exons). Colors correspond to those used for each subunit in the crystal structure in C: blue, 
RNASEH2A; green, RNASEH2B; red/pink, RNASEH2C. Except for variants L202S and D205E in RNASEH2A, all variants occurred with allele frequencies of 
<0.002 (Table 1). Variant A156A in RNASEH2C affected splicing (Table 1). (C) RNase H2 residues (yellow sticks) affected by missense mutations identified 
in SLE patients, mapped on the structure of the human enzyme (PDB ID, 3PUF; ref. 63).
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mental Table 1). Therefore AGS parents appear 
to have an intermediate autoimmune phenotype, 
consistent with a recent report that identified an 
increased risk of autoimmune disease in families 
of AGS patients (27).
Hypomorphic variants of RNASEH2 genes are 
associated with SLE. We next sequenced the genes 
encoding all 3 RNase H2 subunits (RNASEH2A, 
RNASEH2B, and RNASEH2C) in 600 SLE patients 
and 1,056 controls and identified rare variants, 
both nonsynonymous and splice site mutations, 
associated with SLE (combined P = 0.0011; OR, 
2.00; 95% CI, 1.32–3.06; Figure 1B and Table 1). 
These patients mainly showed cutaneous involve-
ment, photosensitivity, arthritis, lymphopenia, 
and autoantibody formation; internal organ 
involvement was less frequent (Supplemental 
Table 2). Mutations were found in each of the 3 
RNase H2 subunits, affecting residues that appear 
to be evenly distributed throughout the heterotri-
meric enzyme complex (Figure 1, B and C). As all 
3 subunits are required for enzyme activity (28, 
29), we examined the effect of all mutations on 
recombinant enzyme activity, complex stability, 
and nuclear localization (Figure 2, A and B, and 
Supplemental Figure 1). Of the 18 SLE-associated 
mutations, 17 (94%) impaired RNase H2 function, 
with mutations either directly impairing enzyme 
activity, causing reduced complex stability, or 
altering subcellular localization (Figure 2, A and B, 
Supplemental Table 3, and Supplemental Figure 1). 
We therefore concluded that these variants affect 
cellular enzyme function, which suggests that 
reduced RNase H2 activity confers an increased 
risk for autoimmunity. Notably, RNase H2 func-
tional impairment correlated with risk of SLE: as a 
group, mutations causing mild functional impair-
ment conferred a 1.6-fold relative risk (OR, 1.69; 
P = 0.03), while mutations that severely affect 
RNase H2 function led to a 3.8-fold greater risk 
(OR, 3.94; P = 0.003) (Figure 2C), establishing a 
direct correlation between enzyme function and 
disease susceptibility. Furthermore, perform-
ing burden testing, weighting mutation count by 
severity (see Methods), strengthened the signifi-
cance of the genetic association (P = 0.00026).
To further validate the genetic association in 
the sequenced cohort (set 1), we sought to replicate our findings in 
a second independent cohort of 8,277 European individuals, con-
sisting of 4,212 SLE cases and 4,065 controls (set 2) that had previ-
ously been genotyped for a GWAS (see Supplemental Methods). 
One of the rare variants identified in set 1, rs7247284 (L202S), was 
also genotyped in set 2. This variant showed 1.7-fold enrichment 
among SLE cases in set 1, although it did not by itself reach statis-
tical significance. In the larger cohort of set 2, this L202S variant 
was significantly associated with SLE, after principal component 
analysis to correct for stratification (Supplemental Methods) and 
and complex SLE (10, 14–16), we asked whether heterozygosity 
for RNASEH2 mutations increases the risk of systemic autoimmu-
nity. First, we examined whether parents of AGS patients (obligate 
heterozygous mutation carriers) have subclinical features of SLE. 
Clinical investigation revealed a high occurrence of autoantibod-
ies, with ANAs detected in AGS parents at a substantially higher 
frequency than expected (P < 0.001; Figure 1A and Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI78001DS1). In addition, other autoantibodies 
associated with SLE were also found in AGS parents (Supple-
Table 1. Contribution of rare variants of the RNASEH2 genes to SLE risk  
Variant Position Allele change dbSNPA MAF (%)
All SLE Control
RNASEH2A, chromosome 19
L202S 12,921,186 T>C rs7247284 1.36 1.83 1.09
L202S + D205EB 12,921,196 T>C + T>A rs62619782 0.54 0.58 0.52
E75Q + E294KB 12,918,043, 
12,924,260
G>C + G>A – 0.03 0.08 0.00
E84D 12,918,072 G>T – 0.03 0.00 0.05
A121T 12,918,270 G>A – 0.03 0.08 0.00
K165R 12,920,967 A>G – 0.03 0.00 0.05
A178V 12,921,006 C>T – 0.03 0.08 0.00
K221R 12,923,921 A>G rs143534021 0.06 0.17 0.00
R239C 12,923,974 C>T – 0.03 0.00 0.05
I244V 12,923,989 A>G – 0.03 0.08 0.00
G276R 12,924,206 G>A – 0.03 0.00 0.05
T297A 12,924,269 A>G – 0.03 0.00 0.05
RNASEH2B, chromosome 13
G10R 51,484,240 G>A – 0.03 0.08 0.00
F95L 51,504,859 T>G – 0.03 0.08 0.00
D105A 51,504,888 A>C rs201078944 0.03 0.08 0.00
N152S 51,517,475 A>G rs146451037 0.03 0.00 0.05
A177T 51,519,581 G>A rs75184679 0.12 0.17 0.09
K233Q 51,522,203 A>C – 0.03 0.08 0.00
K248N 51,528,043 A>C – 0.03 0.08 0.00
S277N 51,530,501 G>A – 0.03 0.00 0.05
A287S 51,530,530 G>T rs144408326 0.18 0.33 0.09
RNASEH2C, chromosome 11
E110P 65,487,783 GA>CC – 0.03 0.08 0.00
K90del 65,487,791 AAG/– rs141875736 0.03 0.08 0.00
c.348 + 1G>AC 65,487,686 G>A – 0.03 0.08 0.00
A156AD 65,487,516 G>T rs61736590 0.03 0.08 0.00
Rare variants in RNASEH2A, RNASEH2B, and RNASEH2C were identified by exon resequenc-
ing of 1,656 European individuals: 600 SLE patients and 1,056 controls. Mutation position 
based on human genome assembly GRCh37.p9. Amino acid position based on ENSEMBL  
protein sequences ENSP00000221486, ENSP00000337623, and ENSP00000308193. 
Calculation of MAF was based on the whole dataset. RNASEH2A, P = 0.050; RNASEH2B,  
P = 0.021; RNASEH2C, P = 0.017; RNASEH2A, RNASEH2B, and RNASEH2C combined, P = 0.0011 
(OR, 2.00; 95% CI, 1.32–3.06); Fisher’s exact test. ASNP database ID (http://www.ncbi.nlm.nih.
gov/SNP/). BVariant established to be in cis through sequencing studies. CAlters the donor splice 
site of intron 2. Consequently, intron 2 is not spliced out, resulting in a frame shift (p.F116fs). 
DSynonymous change alters the last base of exon 3 affecting the splice site. Cloning of the 
RNASEH2C cDNA from frozen PBMCs of this patient established that intron 3 was not spliced 
out in 7 of 20 clones. The aberrantly spliced mRNA is predicted to lead to an in-frame insertion 
of 51 amino acids between p.A156 and p.I157.
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moments (see Supplemental Methods), compared with WT cells 
(Figure 3, A–C). To establish that this DNA alkali sensitivity was 
due to embedded ribonucleotides, we also performed single-cell 
gel electrophoresis at neutral pH with and without treatment with 
RNase H2. Under these conditions, an increase in DNA migrating 
from the nucleus after RNase H2 treatment should reflect the pres-
ence of ribonucleotides incorporated in the DNA. Tail moments 
were significantly higher for both RNase H2–deficient MEFs and 
patient fibroblasts compared with WT controls (Figure 3, A, D, and 
E), in keeping with the presence of higher numbers of misincorpo-
rated ribonucleotides in their genomic DNA. Thus, our biochemi-
cal and cellular findings were consistent with the notion that par-
tial loss-of-function mutations in genes encoding the RNase H2 
enzyme complex cause increased levels of embedded ribonucleo-
tides in genomic DNA in both SLE and AGS patients.
SLE and AGS patient fibroblasts have increased p53 signaling 
and reduced cellular proliferation. In RNase H2–null mice, loss of 
enzymatic activity leads to increased embedded ribonucleotides 
and activation of a p53-dependent DNA damage response, result-
ing in arrested cell proliferation and embryonic lethality (23, 24). 
To determine whether reduced RNase H2 function in patients 
with AGS and SLE also causes a DNA damage response, we exam-
ined proliferation rates, cell cycle progression, and p53 activation. 
Patient fibroblasts proliferated significantly slower than did WT 
cells (Figure 4A). Flow cytometry of cells synchronized by serum 
starvation demonstrated that reduced proliferation resulted from 
delayed cell cycle progression, rather than increased apoptosis 
(Figure 4B). This was accompanied by elevated phosphorylation 
of p53 at Ser15 (Figure 4C). In addition, patient cells showed an 
increased number of p16-positive cells as well as cellular senes-
logistic regression resulting in a P value of 0.0046 (additive mod-
el, OR, 1.19; recessive model, OR, 2.31). In an additional approach 
to address that RNASEH2 gene variants in aggregate were associ-
ated with SLE in this second dataset, we imputed variants within 
each of the 3 RNASEH2 genes based on the cleaned GWAS data of 
set 2 using IMPUTE2, previously prephased with SHAPEIT (30). 
Association was explored by aggregated tests using RWAS and 
LRT (version 0.5; ref. 31) including only markers with IMPUTE 
info value > 0.8, sample call rate > 0.9, and linkage disequilibrium 
r2 < 0.5 at various minor allele frequency (MAF) thresholds (0.05, 
0.01, 0.005, and 0.001). After permutation, aggregate analysis 
treating the 3 genes as a single unit (based on the fact that the sub-
units form a single enzyme) resulted in lower P values (e.g., 0.01 
MAF threshold, P = 0.0005; Supplemental Table 4). In summary, 
our findings in 2 independent cohorts support an association of 
variants within the RNASEH2 genes with a risk for SLE.
RNASEH2 mutations impair ribonucleotide removal in AGS and 
SLE patient cells. As removal of misincorporated ribonucleotides 
from genomic DNA is an essential function of RNase H2 (22–24), 
we hypothesized that impaired RNase H2 function causes ribonu-
cleotides to accumulate at a low level in the genomic DNA of patient 
cells. We tested this hypothesis by single-cell gel electrophoresis of 
patient fibroblasts with mutations in RNASEH2C (patient AGS1, 
D39Y/D115fs; patient AGS2, P76L homozygous; patient SLE1, 
c.348 + 1G>A [F116fs] heterozygous) and RNASEH2B (patient 
SLE2, K233Q heterozygous). Under alkaline conditions (that detect 
single-strand breaks and alkali-labile sites such as ribonucleo-
tides), RNase H2–deficient mouse embryonic fibroblasts (MEFs) 
and patient fibroblasts both showed a significant increase in DNA 
migrating from the nucleus, with significantly larger comet tail 
Figure 2. Rare sequence variants impair RNase H2 function in SLE and AGS. RNASEH2 variants identified 
by resequencing caused reduced enzyme activity or complex stability. (A) Effects of RNASEH2 variants on 
recombinant enzyme activity on dsDNA substrate with an embedded ribonucleotide. Cleavage of an RNA/
DNA substrate was similarly affected (data not shown). Mean (n = 3) and SD shown. (B) Thermal stability 
(expressed as thermal shift; ΔTm) of recombinant mutant RNase H2 complexes relative to WT; negative 
values denote less stable complexes. Mean (n ≥ 9) and SEM shown. (A and B) Unless specifically indicated as 
P = NS, activity was significantly different compared with WT (P < 0.01, t test). (C) Burden analysis demon-
strated that increased risk of SLE correlated with functional severity of the RNASEH2 variants. Variant fre-
quencies for neutral, mild, and severe functional consequences (see Supplemental Table 3) were calculated 
using number of occurrences as a percentage of total SLE cases (n = 600) or controls (n = 1,056) respectively. 
Fold change relative to control is also denoted.
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viral infection or circulating nucleic acids released from apoptotic 
cells) and UV light (6, 7), could enhance and prolong IFN produc-
tion in a susceptible individual, to initiate autoimmunity.
Increased CPD formation in ribonucleotide-containing DNA. 
Notably, cutaneous lupus and photosensitivity were the predomi-
nant symptoms of SLE patients carrying RNASEH2 mutations 
(Supplemental Table 2 and Supplemental Figure 5). Furthermore, 
in keeping with the enhanced type I IFN production we observed 
in SLE patient fibroblasts with RNASEH2 mutations, the IFN-
induced proteins MxA and CXCL10 were detectable in lesional 
skin (Figure 5B). As exposure to UV irradiation frequently pro-
vokes flares of cutaneous lupus erythematosus and SLE, these 
clinical observations suggested that impaired RNase H2 function 
might specifically enhance photosensitivity. Consequently, we 
hypothesized that embedded ribonucleotides enhance the sensi-
tivity of genomic DNA to photodamage. We therefore examined 
the formation of CPDs, the most abundant UV light–induced DNA 
lesion. CPDs are formed by the covalent linkage of the ring carbon 
5 (C5) and C6 bonds of adjacent pyrimidines (37). Immediately 
after UVC exposure, CPD formation was significantly higher in 
fibroblasts from AGS and SLE patients compared with WT fibro-
blasts (Figure 6A). Increased CPD formation was also observed 
in patient fibroblasts irradiated with biologically relevant solar-
simulated radiation, which, unlike UVC, is not filtered by the 
atmosphere (Supplemental Figure 6). Differences in CPD staining 
between mutant and WT cells resolved within hours after irradia-
tion (Figure 6A and Supplemental Figure 6), in keeping with pro-
ficient nucleotide excision repair in the patient fibroblasts. There-
fore, rather than difficulty in CPD removal by nucleotide excision 
cence, as shown by β-galactosidase staining (Figure 4, D and E). 
Fibroblasts from patients with SLE or AGS were also more likely 
to harbor γH2AX and p53-binding protein (53BP1) foci (Figure 
4F), indicative of double-strand DNA (dsDNA) breaks at a low 
frequency, whereas UVC-induced dsDNA breaks in fibroblasts of 
patients and controls were repaired with similar efficiency (data 
not shown). Together, these findings demonstrated activation of 
a low-level DNA damage response in the absence of exogenous 
genotoxic stress in AGS and SLE patient cells.
Enhanced induction of type I IFN in RNASEH2 mutant cells. As 
induction of DNA damage response signaling can stimulate IFN 
production (32), this may directly contribute to autoimmunity in 
SLE and AGS (33). Transcriptional profiling of fibroblasts revealed 
remarkably similar profiles in patients with SLE and AGS (Supple-
mental Figures 2–4). Although we did not detect constitutive type I 
“IFN transcription in unstimulated patient cells (Figure 5A), quan-
titative RT-PCR analysis demonstrated upregulation of IFN-stim-
ulated genes (Supplemental Figure 2). We therefore hypothesized 
that the observed DNA damage response in patient fibroblasts, 
although insufficient in itself to induce IFN secretion, sensitizes 
the cells to mount type I IFN responses in response to external 
stimuli. Given that nucleic acids can trigger type I IFN production 
and promote systemic autoimmunity (34–36), we next challenged 
patient fibroblasts with polyinosinic:polycytidylic acid [poly(I:C)], 
a synthetic dsRNA analog; indeed, these displayed stronger and 
more sustained IFNB expression compared with WT cells (Figure 
5A). The type I IFN response was further enhanced when cells 
were also exposed to UVC irradiation (Figure 5A). These findings 
suggest that well-known triggers of SLE, nucleic acids (either from 
Figure 3. Increased levels of misincorporated ribonucleotides in genomic DNA in cells from patients with AGS and SLE. (A) Representative images of 
comets formed by human fibroblasts after single-cell electrophoresis at alkaline and neutral pH without or with RNase H2 pretreatment. Scale bar:  
50 μm. (B and C) Quantification of Olive tail moment (see Supplemental Methods) after alkaline comet assay, indicative of single-strand DNA breaks, in 
(B) fibroblasts from SLE patients (SLE1 and SLE2), AGS patients (AGS1 and AGS2), and WT controls (WT1 and WT2) and in (C) Rnaseh2b-deficient or WT 
MEFs. (D and E) Quantification of Olive tail moment in comet assays of human fibroblasts and MEFs (as in B and C, respectively) under neutral condition, 
without and with RNase H2 pretreatment, showed increased Olive tail moments for RNase H2–deficient cells, consistent with elevated levels of embed-
ded ribonucleotides in their genomic DNA. (B–E) Mean and SEM of 30–70 cells from 3 independent experiments per cell line. **P < 0.01, ***P < 0.001 
versus WT2 (B and D) or WT (C and E), t test.
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repair, the patient DNA appeared intrinsically more sensitive to 
UV exposure, and we postulated that embedded ribonucleotides 
might enhance CPD formation.
Thymine dimerization in DNA is an ultrafast photoreaction 
dependent on DNA conformation prior to light absorption (38, 
39). To determine the molecular basis of enhanced CPD forma-
tion, we examined the structural consequences of the presence 
of a ribonucleotide embedded in a DNA duplex. The Dickerson 
dodecamer, a dsDNA oligonucleotide, is a prototypic B-form DNA 
(40). Unlike DNA, RNA adopts an A-form helix, which is more 
resistant to photodamage (41, 42). However, the presence of sin-
gle riboguanosine positioned 3 bases upstream of 2 adjacent thy-
mines within the Dickerson dodecamer does not convert it from 
B- to A-form DNA (43). We therefore examined instead whether 
Figure 4. Reduced proliferation and increased DNA damage response activation in SLE and AGS patient fibroblasts. (A) Reduced proliferation rate of 
fibroblasts from patients with SLE (SLE1 and SLE2) and AGS (AGS1 and AGS2) compared with the mean of 5 WT control fibroblast lines (2 children,  
3 adults). P < 0.05 (3 and 5 hours), P < 0.001 (7 hours), AGS1 vs. WT, t test. (B) Cell cycle analysis of propidium iodide–stained fibroblasts after synchroniza-
tion in G1 by 24 hours of serum starvation. Representative flow cytometry images depict cell cycle delay in RNase H2–deficient fibroblasts. (C) Activation 
of a p53-dependent DNA damage response in patient fibroblasts in the absence of exogenous genotoxic stress, as shown by increased levels of phos-
phorylated p53 (Ser15). The same immunoblot probed for β-actin shows equal loading. (D) Increased number of p16-positive cells in RNase H2–deficient 
fibroblasts, measured by flow cytometry. (E) Increased senescence in patient fibroblasts, measured by β-galactosidase staining. Scale bar: 100 μm. (F) 
Increased dsDNA damage in RNase H2–deficient human fibroblasts. dsDNA breaks were visualized by immunostaining of γH2AX (red) and 53BP1 (green). 
The number of nuclei with 0–3 foci stained for both (yellow) among 50 randomly selected cells was quantified. Original magnification, ×400. Data are 
mean and SEM (D and E) or mean and SD (A, B, and F) of 3 independent experiments per patient and 5 independent WT control cell lines (A and B) or of 4 
experiments per patient and 5 WT controls (D–F). (B–F) *P < 0.05, **P < 0.01, #P < 0.001 versus WT, t test.
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this ribonucleotide enhances a stereochemical dimerizable con-
formation resulting from altered thymine stacking. We calculated 
the dihedral angles between the covalent C5-C6 bonds as well 
as pyrimidine ring planes of the adjacent thymines based on the 
NMR structures of the Dickerson dodecamer (1NAJ; ref. 44) and 
the ribonucleotide-containing dodecamer (2L7D; ref. 43). Com-
parison of the dihedral angles revealed structural changes indica-
tive of an increase in colinearity between C5-C6 covalent bonds 
as well as in coplanarity between pyrimidine rings (Figure 6, B and 
C). Thus, the presence of a ribonucleotide within the dodecamer 
induces conformational changes of the adjacent thymines that 
render them more sensitive to photoreactive dimerization. Nota-
bly, isolated DNA of RNase H2–deficient human fibroblasts and 
MEFs displayed a higher rate of CPD formation than WT controls 
(Figure 6D), which indicated that enhanced CPD formation was 
an intrinsic feature of the ribonucleotide-containing DNA. Finally, 
to experimentally confirm that enhanced photodamage in mutant 
cells may be directly caused by an alteration in DNA structure 
imposed by ribonucleotides, we examined CPD formation in syn-
thetic DNA oligonucleotides containing the dodecamer sequence 
with an embedded ribonucleotide. These also had enhanced 
UVC-induced CPD formation (Figure 6E). We therefore conclud-
ed that increased CPD formation in ribonucleotide-containing 
DNA could contribute to enhanced sensitivity of patients with 
RNASEH2 mutations to UV irradiation.
Discussion
Here we report that rare genetic variants in the genes encoding 
the RNase H2 enzyme increase the risk for systemic autoimmu-
nity. First, we delineated an intermediate phenotype of subclini-
cal autoimmunity among heterozygous parents of AGS patients by 
demonstrating an increased occurrence of ANAs. The appearance 
of autoantibodies is one of the first signs of systemic autoimmu-
nity and reflects a series of immunologic events that typically pre-
cedes the onset of clinical symptoms by several years. For exam-
ple, the presence of ANAs or anti-Ro, anti-La, or antiphospholipid 
antibodies has been shown to increase the risk for clinical disease 
by at least 40-fold (45). Second, by resequencing the RNASEH2 
genes, we identified an excess of rare variants in patients with 
SLE compared with healthy controls, with biochemically assessed 
functional severity correlating with SLE risk. We replicated this 
finding in an independent cohort, in which imputed variants from 
a large GWAS dataset show significant association in aggregate 
(P = 0.0005). Future independent, large-scale, sequence-based 
studies will be valuable in further substantiating this association. 
Taken together, these findings support a role for RNASEH2 genes 
as a risk factor for systemic autoimmunity, and moreover highlight 
the potential contribution of rare variants to the heritability of SLE.
Our findings suggest that RNase H2 dysfunction may contrib-
ute to the multistep initiation of SLE autoimmunity at several stag-
es, by enhancing the type I IFN response to both endogenous and 
external factors (Supplemental Figure 7). First, systemic autoim-
munity may be promoted by innate immune recognition of nucleic 
acid intermediates generated during repair of DNA damage that 
results from ribonucleotide misincorporation or incomplete reso-
lution of R-loops in cells with impaired RNase H2 activity (25). 
Indeed, in Trex1–/– cells, type I IFN activation has been attributed 
to stimulation of pattern recognition receptors by cytosolic DNA 
(33, 46, 47), which may originate from DNA repair processes (33). 
However, IFN may also be induced by cytoplasmic nucleic acids 
arising from replication intermediates of retroviruses/retroele-
ments in TREX1- and/or RNase H2–deficient cells (46, 48). Sec-
Figure 5. Type I IFN production by patient 
cells is enhanced in response to nucleic 
acids and UV light. (A) Increased type I IFN 
activation in fibroblasts of patients with 
SLE and AGS compared with WT controls 
after treatment with poly(I:C) and/or UVC 
irradiation (30 J/m2 UVC for 3 seconds). 
Samples were processed after subsequent 
culture for 4, 8, and 24 hours. IFNB mRNA 
was normalized to GAPDH mRNA. Mean 
and SEM of ≥3 independent experiments 
per group (SLE and AGS, n = 2; WT, n = 5). 
*P < 0.05, **P < 0.01, ***P < 0.001 versus 
poly(I:C) at the same time point, Mann-
Whitney U test. (B) Lesional skin from lupus 
patients carrying the indicated mutations 
in RNASEH2B and RNASEH2C showed high 
expression of type I IFN–inducible MxA (red) 
and CXCL10 (green). Scale bars: 100 μm.
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damage signaling. Even without transcriptional IFN induction, 
priming of IFN signaling through upregulation of pathway com-
ponents like IRF7 (53) could explain the enhanced sensitivity of 
cells with impaired RNase H2 function to nucleic acids and UV 
irradiation (Supplemental Figure 7). Innate immune activation 
induced by a DNA damage response may be further enhanced 
by increased CPD formation of ribonucleotide-containing DNA 
upon UV irradiation. Although we did not observe increased sen-
sitivity to apoptosis in patient cells in response to UV light (Supple-
mental Figure 8), increased DNA damage in RNase H2–deficient 
skin cells could render them more susceptible to apoptosis upon 
repeated exposure to UV light, further promoting the release of 
immunostimulatory nucleic acids. Such UV light–induced enrich-
ment of lupus nucleic acid–related autoantigens (e.g., Ro/SSA 
and La/SSB) has been observed in apoptotic surface blebs on 
keratinocytes (54). As UV light is a major trigger of SLE symp-
toms (7), our data provide an additional mechanism for the pho-
tosensitivity observed in SLE patients and illustrate the interplay 
of genetic and environmental factors in disease initiation. Given 
that type I IFN activation underlies initiation of inflammation and 
ond, p53 activation in AGS/SLE patient cells may more directly 
promote innate immune signaling, perhaps through the activa-
tion of p53 target genes that stimulate type I IFN or that induce 
enhanced sensitivity to type I IFN stimuli (32, 49).
AGS and SLE patient fibroblasts do not constitutively express 
detectable levels of IFN-β, although very weak or intermittent 
type I IFN production cannot be excluded (50). However, tran-
scriptional regulation of IFN gene expression is complex, with 
multiple positive and negative regulatory elements (51), and low-
level accumulation of intracellular nucleic acids or activation of 
p53 signaling may therefore not be sufficient to induce type I IFN. 
Indeed, the IRF3/IRF7/STING/TBK1-dependent activation of 
antiviral genes in Trex1–/– cells occurs without induction of type I 
IFN (52), despite IRF3 and IRF7 being established transcriptional 
activators of IFN-β (53). Consistent with this, transcriptional pro-
filing of patient fibroblasts revealed induction of both p53-depen-
dent genes and antiviral IFN-induced genes in the absence of 
detectable type I IFN activation. As p53 induction has also been 
reported in TREX1-null mouse cells (33), this raises the possibil-
ity of a common pathogenic mechanism in AGS involving DNA 
Figure 6. Increased sensitivity to photodamage in ribonucleotide-containing DNA. (A) Increased CPD formation in RNase H2–deficient fibroblasts (SLE1, 
SLE2, AGS1, and AGS2) compared with WT in response to 20 J/m2 UVC, measured immediately or 7 and 24 hours after irradiation. Box plots depict inter-
quartile range (box), mean (square), median (line) and SD (whisker) of ≥3 independent experiments per patient and for 5 WT cell lines. *P < 0.05,  
**P < 0.01, ***P < 0.001 versus WT, t test. (B and C) Dihedral angles between covalent C5-C6 bonds (B) and pyrimidine ring planes (C) of 2 consecutive 
thymidines of the unmodified (1NAJ) and the ribonucleotide-containing (2L7D) Dickerson dodecamer. Ribonucleotide substitution increased colinearity 
between C5-C6 covalent bonds and coplanarity between pyrimidine rings, enhancing the probability of a photoreactive dimerization. For each dodecamer, 
5 structures deposited in PDB were compared. Mean and SD shown. ***P < 0.001 versus 1NAJ, t test. (D) CPD formation in genomic DNA from fibroblasts 
of individual RNase H2–deficient versus WT patients and from Rnaseh2b–/– versus WT MEFs (n = 2 per group). Representative dot blot and mean intensi-
ties with SEM of 3 independent experiments are shown. *P < 0.05, **P < 0.01, ***P < 0.001 versus WT, t test. (E) CPD formation in double-stranded 
concatamers of chimeric DNA oligonucleotides containing 3 Dickerson dodecamer sequences in tandem. Replacement of a deoxyriboguanosine at position 
4 of the dodecamer by a riboguanosine (R) is indicated.
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introduced by site-directed mutagenesis (QuikChange Lightning; Agile-
nt) or amplified from patient cDNA. HeLa cells were grown on coverslips 
in DMEM with 10% FCS, 2 mM l-glutamine, and antibiotics and trans-
fected with 200 ng plasmid DNA of each fluorescently tagged RNase H2 
subunit using Fugene HD (Roche). Cells were fixed in 4% paraformal-
dehyde and mounted in Vectashield Mounting Medium with DAPI (Vec-
tor Labs). Confocal microscopy was performed using a Leica TCS SP5 II 
with a ×40/1.25 oil objective. For subcellular localization, 300 cells total 
were analyzed per mutation in 3 independent experiments.
Immunohistochemistry. Paraffin-embedded skin biopsies were cut 
into 2- to 5-μm sections, rehydrated, and boiled in sodium citrate buf-
fer (pH 6.0). Sections were stained with mouse anti-MxA (provided 
by O. Haller, Freiburg University, Breisgau, Germany; 1:400 dilution) 
or rabbit anti-CXCL10 (Bioss; 1:100 dilution), followed by staining 
with EnVision G|2 System/AP Rabbit/Mouse (Dako) or Alexa Fluor 
488–conjugated goat anti-mouse IgG (Invitrogen; 1:200 dilution), 
respectively. Sections were counterstained with Mayer’s hematoxylin 
(Merck). For staining of dsDNA breaks, fibroblasts grown on coverslips 
were fixed with 4% paraformaldehyde, permeabilized with 0.5% Tri-
ton X-100 in PBS, and probed with mouse anti-γH2AX (Ser139; Novus 
Biologicals, clone 2F3; 1:500 dilution) and rabbit anti-53BP1 (Novus 
Biologicals; 1:2,000 dilution). Slides were then probed with Alexa 
Fluor 546–conjugated goat anti-mouse IgG or Alexa Fluor 488–conju-
gated goat anti-rabbit IgG (Molecular Probes), respectively, mounted 
in Vectashield Mounting Medium with DAPI (Vector Labs), and ana-
lyzed with a Zeiss Axioimager A1 microscope. For quantification, the 
number of double-stained dots was counted in 50 randomly selected 
cells per slide. For detection of CPDs, cells grown on coverslips were 
fixed with methanol (–20°C) and acetone. DNA was denatured in 0.1 N 
NaOH. Cells were then dehydrated with increasing concentrations of 
ethanol (70%–100%) and incubated with mouse anti-CPD (Kamiya 
Biomedical Co., clone KTM53; 1:1,000 dilution) followed by stain-
ing with Alexa Fluor 488–conjugated goat anti-mouse IgG (Molecular 
Probes; 1:200 dilution). The mean fluorescence intensity from 50 cells 
per slide was determined using Image J.
RT-PCR. Total RNA from fibroblasts was extracted with the 
RNeasy Mini Kit (Qiagen) followed by DNase I digestion. IFNB expres-
sion was determined by quantitative real-time RT-PCR using Taqman 
Universal PCR Master Mix (Applied Biosystems) on an ABI7300 and 
normalized to GAPDH expression, or using iQ SYBR Green Supermix 
(Bio-Rad) on an Mx3005P qPCR system (Agilent) and normalized to 
HPRT1 (Supplemental Table 6).
Western blotting. Fibroblasts were lysed in RIPA buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM 
sodium orthovanadate, 20 mM sodium fluoride) supplemented with 
1× Complete Protease Inhibitor Cocktail and 1× PhosSTOP phospha-
tase inhibitors (Roche). 5 μg total protein was subjected to SDS-PAGE 
followed by Western blotting using antibodies against phosphorylated 
p53 (Ser15) (Santa Cruz; 1:200 dilution) and β-actin (Sigma-Aldrich, 
clone AC-74; 1:10,000 dilution). Immunoreactive signals were detect-
ed by chemiluminescence (Lumi-Light PLUS; Roche).
RNase H2 activity and thermal stability assays. Recombinant RNase 
H2 complexes were purified after expression in E. coli and used in a 
FRET-based fluorescent substrate release assay to determine enzyme 
activity, as previously described (29). Thermal stability assays were 
performed using the fluorescence-based thermal shift (ThermoFluor) 
method, as previously described (29).
autoimmunity in AGS and SLE, targeting the IFN axis by type I 
IFN blockade may be of potential therapeutic efficacy. Indeed, 
IFN-α antagonists have been tested in SLE patients in clinical tri-
als with promising results (55), while JAK inhibition was recently 
reported to ameliorate symptoms in patients with the type I IFN–
driven STING-associated vasculopathy (56). TREX1 has been 
implicated in the restriction of retroelements by metabolizing 
reverse-transcribed retroelement-derived RNA (46), raising the 
possibility that retroelement-derived RNA/DNA hybrids may act 
as substrates of RNase H2. As RNA/DNA hybrids were previously 
shown to act as a molecular pattern sensed by TLR9 (57), accrual 
of retroelement-derived RNA/DNA hybrids in RNase H2–defi-
cient cells could contribute to innate immune activation. Further 
investigations are required to assess the potential role of RNase 
H2 in retroelement restriction.
In conclusion, our genetic and functional data implicate RNase 
H2 in SLE, establishing a ribonuclease alongside several DNA 
nucleases in SLE pathogenesis. Whereas DNase I, DNase II, and 
DNase 1L3 are involved in clearance of circulating nucleic acids 
(34–36, 58), RNase H2 and TREX1 (16) are intracellular nucleases 
involved in DNA replication and repair, and now have established 
roles in systemic autoimmunity. Furthermore, the DNA damage 
pathway activation and enhanced UV-induced CPD formation 
observed in cells of patients with RNASEH2 mutations suggest a 
role for DNA damage–associated pathways in the pathogenesis of 
autoimmunity, which warrants further investigation.
Methods
Human samples. Samples from 600 SLE patients from Germany (n = 471) 
and the United Kingdom (n = 129) were collected as previously 
described (16, 59). SLE phenotypes were defined according to the diag-
nostic criteria by the American College of Rheumatology (60, 61). Con-
trol samples (n = 1,056) were obtained from the blood donation pro-
grams at University Hospital Dresden and University Hospital Bonn. 
See Supplemental Methods for details of the replication cohort.
Mutation analysis. The coding sequences of RNASEH2A, RNA-
SEH2B, and RNASEH2C were amplified by PCR from genomic DNA 
using gene-specific primers (Supplemental Table 5). Both strands of the 
purified PCR products were sequenced using fluorescent dye termina-
tor chemistry on ABI 3730 or ABI3010xl instruments. All identified 
variants were validated by resequencing. Sequence reads were analyzed 
using Vector NTI, DNASTAR, Sequencher, and Mutation Surveyor.
Autoantibody testing. Routine serological tests were carried out 
at the diagnostic laboratory of the Institute of Immunology, Tech-
nische Universität Dresden. ANAs were determined using Hep-2 cells; 
extractable nuclear antigens were analyzed by immunodiffusion. 
Data on ANAs from a reference population were obtained from 1,000 
blood donors (samples collected at the Institute of Immunology, 
Technische Universität Dresden).
Cells, transfection, and confocal microscopy. Human fibroblasts were 
derived from skin biopsies and maintained in DMEM with 10% FCS, 
2 mM l-glutamine, and antibiotics. In all experiments, passage-matched 
fibroblasts (passages 4–11) were used. Rnaseh2b-deficient MEFs were 
generated as previously described (24). N-terminally GFP-tagged WT 
RNase H2 subunits were cloned into pEGFP-C1. GFP was replaced by 
YFP, CFP, or mCherry using AgeI and BsrGI. pRSET-mCherry was pro-
vided by R.Y. Tsien (UCSD, La Jolla, California, USA). Mutations were 
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www.PDB.org). The dihedral angle between the covalent bonds link-
ing C5 and C6 of the 2 consecutive thymidines (θ1; Figure 6B) that 
constitute the 4 members of the cyclobutane ring reflects the degree 
of colinearity. The angle is 0° when the 2 bonds are perfectly colinear 
and 90° when perpendicularly arranged. The dihedral angle between 
the 2 vectors perpendicular to the planes defined by the heterocyclic 
rings of the adjacent thymidines (θ2; Figure 6C) indicates the degree of 
coplanarity. This angle is 0° when the 2 heterocyclic rings are perfectly 
coplanar and 90° when perpendicularly arranged.
Comet assay and RNA sequencing. See Supplemental Methods 
and Supplemental Figures 2–4 for details. RNA sequencing data were 
deposited in GEO (accession no. GSE63755).
Statistics. Data are presented as mean ± SD or mean ± SEM as 
indicated. Statistical significance was determined by 2-tailed Stu-
dent’s t test, Fisher’s exact test, or Mann-Whitney U test as indicated. 
A P value less than 0.05 was considered statistically significant. The 
number of mutations between cases and controls was compared with 
a 2 × 2 contingency table using 2-sided Fisher’s exact test. The burden 
analysis was carried out after grouping the mutations into 3 categories 
(neutral, mild, and severe functional impact) using logistic regression; 
disease ORs reported are for comparisons of mutation carriers and 
noncarriers within the same category. Finally, logistic regression was 
also carried out on a continuous mutation burden, using a weighted 
approach (62), giving mutations with mild functional defects a con-
servative score of 0.5, those with severe functional defects a score of 1, 
and neutral ones a score of 0. Severity of functional deficiency was 
determined using data from enzyme activity, complex stability, and 
nuclear localization studies (Supplemental Table 3). Statistical analy-
sis was carried out using SPSS and R (www.r-project.org). See Sup-
plemental Methods for association analysis of the replication cohort 
using imputation and aggregated analysis.
Study approval. DNA samples from SLE patients and controls for 
genetic analysis were collected with written informed consent after 
approval by the institutional ethics review boards of the participating 
centers. Human primary fibroblasts were derived from skin biopsies 
with written informed consent from patients or their parents. The 
study was approved by the ethics committee of the Medical Faculty, 
Technische Universität Dresden.
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Cell cycle analysis and β-galactosidase staining. Fibroblasts were 
synchronized by serum starvation for 24 hours. At the indicated 
time points after cultivation in complete growth medium, cells were 
harvested, fixed, and stained with propidium iodide. Flow cytom-
etry was performed on a FACSCalibur instrument using CellQuest 
software (both BD). Fibroblasts were stained using the Senescence 
β-Galactosidase Staining Kit (Cell Signaling) and analyzed by light 
microscopy. For flow cytometry analysis of p16, fibroblasts were 
fixed in –20°C methanol, permeabilized with 0.01% Tween-PBS, and 
stained with Alexa Fluor 488–conjugated mouse anti-p16 antibody 
(Santa Cruz, catalog no. sc-1661).
UV irradiation. Fibroblasts were grown in 6-well plates or on cov-
erslips and exposed to UVC light (254 nm; low-pressure mercury lamp) 
at a radiation dosage of 20 or 30 J/m2, or to solar-simulated radiation 
(Arimed B lamp) at a radiation dose of 100 J/m2. UV lamps were cali-
brated using a thermopile TS 50-1 (Physikalisch-technische Werkstät-
ten). For the experiment described in Figure 5A, cells were incubated 
with 100 μg/ml poly(I:C) (Invivogen) for 3 hours. Cells were washed 
with PBS, and fresh medium was added following UVC irradiation. 
At the indicated times after irradiation, cells were processed for RNA 
isolation and RT-PCR or fixed for CPD staining. For flow cytometry 
analysis of CPDs, cells were fixed in 4% formaldehyde, permeabilized 
with 0.5% Triton X-100 (in PBS) and stained with mouse anti-CPD 
(Kamiya Biomedical Co., clone KTM53) and goat F(ab′)2 anti-mouse 
Alexa Fluor 488 (Molecular Probes).
South Western blotting. After UV irradiation, genomic DNA was 
isolated as follows. Cell pellets were resuspended in 200 μl lysis buffer 
(100 mM Tris, 5 mM EDTA, 0.2% SDS, 0.2 M NaCl, pH 7.0) containing 
1 mg/ml proteinase K and centrifuged at 13,000 g in an Eppendorf mini-
fuge. The supernatant was mixed with an equal volume of isopropanol, 
incubated at –80°C for 1 hour, and centrifuged at 13,000 g. Pellets were 
washed with 70% and 100% ethanol, air dried, and dissolved in TE 
(pH 7). 400 ng genomic DNA in a volume of 200 μl 150 mM NaCl was 
then exposed to 30 J/m2 UVC in a 6-well plate. After mixing with 200 μl 
NE buffer (10 mM EDTA, 0.4 M NaOH), samples were denatured at 95°C 
and placed on ice. Next, DNA samples were blotted to a nitrocellulose 
membrane pre-soaked in 2× SSC using a dot blotter and vacuum pump. 
The membrane was washed in neutralization buffer (1 M Tris-HCl, 2 M 
NaCl, pH 7) and baked at 80 °C for 2 hours, followed by blocking in 4% 
milk in PBS and probing with mouse anti-CPD (Kamiya Biomedical Co., 
clone KTM53; 1:1,000 dilution). After 3 washes in PBS with 1% Tween, 
the membrane was incubated with anti-mouse IgG (Dako; 1:1,000 dilu-
tion) for 1 hour. Immunoreactive signals were detected by chemilumi-
nescence. Signal density was determined using Image J. DNA oligonu-
cleotides (BioSpring) containing the Dickerson dodecamer sequence 3 
times in a row with or without riboguanosine (underlined) at position 4 
(oligo 1, CGCGAATTCGCG-CGCGAATTCGCG-CGCGAATTCGCG; 
oligo 2, CGCGAATTCGCG-CGCGAATTCGCG-CGCGAATTCGCG; 
oligo 3, CGCGAATTCGCG-CGCGAATTCGCG-CGCGAATTCGCG) 
were concatamerized by heating to 96°C followed by slow cooling to 
room temperature. 2 nmol of each of the oligonucleotides was then 
exposed to UVC for 20 minutes and subjected to South Western dot 
blotting using anti-CPD antibody.
Modeling of Dickerson dodecamers. Dihedral angles were measured 
from atomic coordinates within each strand of the 5 representative 
models of the modified (1NAJ; ref. 44) and unmodified (2L7D; ref. 43) 
NMR Dickerson structures deposited in the Protein Data Bank (PDB; 
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